Autologous Muscle Tissue Regeneration
In a first step a small muscle biopsy taken from the patient under local anesthesia.
Muscle precursor cells (MPCs) are isolated from the Biopsy. These cells are expanded under strictly monitored conditions. Once, the required cell number is reached, the cells are harvested.
The quality of these cells is tested by an external, certified laboratory before the product is released.
The final product is prepared and transported to the hospital where it is injected into the damaged muscle of the patient.
Once injected, the MPCs begin to differentiate, form new muscle fibers and connect with existing muscle tissue leading to regeneration of the muscle.
For over a decade, pre-clinical and Proof of Concept studies were conducted in the tissue engineering laboratory of Prof. Eberli at the University of Zurich. Based on these results, the Swiss authorities gave their approval for a phase I clinical trial, focusing on the treatment of stress urinary incontinence in women, which was completed in 2021. Phase II, which will further investigate the efficiency of this therapy was initiated in September 2022 and is currently recruiting patients.